Anti-obesity Drugs Landscape and Its Impact on Medical Devices Industry
The blog discusses the significant advancements in the anti-obesity drug market, particularly with the approval of Tirzepatide (Zepbound) in late 2023. This drug, along with others like Eli Lilly’s Retatrutide, has shown remarkable efficacy in weight loss, leading to a projected market value exceeding $100 billion by 2030. The article explores how these drugs, which can achieve substantial weight reductions, are transforming treatment approaches and patient health outcomes.